The Latest Breaking News from Laura Chico

Biogen stock has mostly trended sideways this year, but that could soon change with up to $10 billion in dry powder, an analyst said Tuesday.

Jazz stock toppled Thursday — but shares of key rival Praxis surged — after its essential tremor drug failed in midstage testing.

Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.

Apellis Pharmaceuticals’ (APLS) stock has jumped more than 25% year-to-date based on FDA approval for treating geographic atrophy. Despite the breakthrough, the company’s ability to scale up production remains a concern. Moreover, its closest competitor is also close to getting approval. Given its poor financials, stretched valuation, and weak profitability,…

A kidney disease treatment from Vera lagged rivals from Chinook and Otsuka, analysts said Wednesday as the biotech stock plummeted.

The neuroscience renaissance is here. Biotech stocks are soaring this year on expectations for new treatments in brain-health disorders.

Apellis reported an unexpected delay for its eye-disease treatment, leading APLS stock to crash and taking shares of Iveric with it.

The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.

Karuna Therapeutics topped expectations Monday in a study of its schizophrenia treatment, and the biotech stock soared to a record high.